- The conversion of a normal proto-oncogene into an oncogene is one of the fundamental molecular events in cancer development. Proto-oncogenes encode proteins that normally regulate cell growth, proliferation, survival, differentiation, metabolism, and communication with the surrounding environment. Their activity is therefore essential for normal physiology. Cancer can arise when genetic or regulatory alterations cause these genes to become persistently active, excessively expressed, structurally altered, or placed under inappropriate control. The resulting oncogenic activation can produce an oncoprotein or cause excessive activity of an otherwise normal protein.
- Oncogene activation can occur through several distinct mechanisms, and the mechanism often determines how the resulting protein behaves. A mutation may create a protein that is constitutively active, whereas gene amplification may simply increase the amount of an otherwise normal protein. Overexpression can result from changes in transcriptional regulation, while chromosomal rearrangements can either place a proto-oncogene under the control of a powerful regulatory element or generate a new fusion oncogene. Although these mechanisms differ, they can ultimately converge on persistent signaling that promotes cancer-cell proliferation and survival.
- One of the most important mechanisms is activating mutation. A mutation can alter the amino-acid sequence of a protein in a way that increases its activity or prevents normal inactivation. Such mutations are often described as gain-of-function mutations because they give the protein a new or excessive functional property. RAS proteins provide a classic example. Normal RAS cycles between active and inactive states, allowing cells to respond temporarily to extracellular growth signals. Certain mutations interfere with the mechanisms that switch RAS off, resulting in prolonged signaling through downstream pathways such as the MAPK pathway and PI3K–AKT pathway.
- The precise position of a mutation can be extremely important. Some amino-acid substitutions alter catalytic activity, others interfere with regulatory interactions, and some affect protein stability or interactions with inhibitory proteins. Consequently, oncogenic mutations are not simply random changes in DNA. Their effects depend on where they occur within the protein and how the affected region contributes to its molecular function. This connects oncogene activation with the study of protein domains, functional motifs, protein structure, and molecular interactions.
- Another major mechanism is gene amplification. During tumor development, genomic regions containing proto-oncogenes can become duplicated many times, resulting in multiple copies of the gene within a cancer cell. Increased gene copy number can lead to increased RNA and protein production. If the encoded protein promotes proliferation or survival, its excessive abundance can generate persistent oncogenic signaling. Amplification can occur as part of large chromosomal changes or as focal amplification of a relatively small genomic region.
- HER2 amplification is an important example of this mechanism. HER2 encodes a receptor tyrosine kinase involved in cellular signaling. Increased HER2 gene copy number can result in elevated receptor abundance at the cell surface and enhanced downstream signaling. The example illustrates an important principle of oncogene activation: the protein itself does not necessarily need to contain an activating mutation. Increasing the quantity of a growth-promoting protein can be sufficient to disrupt normal cellular regulation.
- Gene amplification can sometimes produce very large increases in protein abundance. Cancer cells may contain multiple copies of an oncogene either integrated into abnormal chromosome structures or present in extrachromosomal DNA elements. These alterations can change dynamically during tumor evolution and treatment, contributing to differences between cancer-cell populations.
- A related mechanism is oncogene overexpression. Overexpression means that a gene produces substantially more RNA or protein than is normal for that cellular context. Gene amplification is one possible cause, but overexpression can also result from altered promoters, enhancers, transcription factors, chromatin states, messenger RNA stability, translation, or protein degradation. Thus, an oncogene can become abnormally active without necessarily undergoing a coding-sequence mutation or gene amplification.
- Changes in gene regulation can be particularly important because cancer cells frequently reorganize their transcriptional programs. A proto-oncogene may become positioned within a regulatory environment that promotes inappropriate expression. Alternatively, alterations in transcription factors or epigenetic regulators can indirectly increase expression of oncogenic genes. These mechanisms demonstrate why oncogene activation is not exclusively a problem of DNA sequence changes within the oncogene itself.
- Chromosomal rearrangements provide another powerful mechanism for oncogene activation. Chromosomes can undergo translocations, inversions, deletions, duplications, and other structural changes. If a rearrangement moves a proto-oncogene next to a highly active regulatory element, the gene may become excessively expressed. This type of mechanism can produce a large increase in protein abundance without changing the protein’s amino-acid sequence.
- Chromosomal rearrangements can also create fusion genes. In this situation, two previously separate genes become joined, producing a hybrid gene whose protein product contains domains derived from both original proteins. The resulting fusion oncoprotein may have a new biochemical activity, altered cellular localization, abnormal protein interactions, or constitutive signaling activity. Fusion oncoproteins are particularly important in several hematological malignancies and solid tumors.
- The BCR-ABL fusion is one of the best-known examples. A chromosomal translocation produces a BCR-ABL fusion gene encoding a constitutively active tyrosine kinase. Because the kinase remains active independently of normal regulatory signals, it continuously stimulates pathways that promote proliferation and survival. The discovery of this molecular alteration provided an important foundation for targeted treatment with BCR-ABL kinase inhibitors.
- Some oncogenic rearrangements primarily affect transcriptional regulation rather than protein structure. A proto-oncogene can be moved near a strong enhancer, causing its expression to become abnormally high. This mechanism is particularly important in certain lymphoid cancers, where rearrangements involving immunoglobulin loci can place growth-promoting genes under powerful regulatory control. The resulting oncogenic effect is therefore caused by inappropriate expression rather than by an abnormal protein sequence.
- Promoter alterations can produce a similar effect. Changes in DNA regulatory regions can increase transcription of a proto-oncogene, while alterations in enhancer activity can establish abnormal gene-expression patterns. In addition, changes in chromatin organization can bring distant enhancers into contact with proto-oncogene promoters. This creates an important connection between oncogene activation and three-dimensional genome organization.
- Oncogene activation can also occur through abnormalities in RNA regulation. Messenger RNA stability, alternative splicing, RNA editing, and non-coding RNAs can influence the amount and form of an oncogenic protein. Certain microRNAs normally suppress proto-oncogene expression, and their loss can therefore indirectly increase oncogenic activity. Conversely, changes in RNA-binding proteins can stabilize oncogenic transcripts and increase protein production.
- Protein-level regulation provides another layer of control. Even when transcription remains relatively normal, an oncogenic protein can accumulate if its degradation is reduced. The ubiquitin–proteasome system normally controls the abundance of many regulatory proteins by selectively marking them for degradation. Changes that stabilize an oncogenic protein can therefore prolong its activity. This illustrates that oncogene activation can involve not only DNA mutations but also disturbances in RNA and protein homeostasis.
- The consequences of oncogene activation depend on the position of the affected protein within the signaling network. An activated receptor may continuously transmit signals into the cell. An intracellular kinase may activate multiple downstream substrates. A small GTPase may remain locked in an active state. A transcription factor may continuously stimulate expression of growth-related genes. These different mechanisms can therefore produce distinct molecular phenotypes while ultimately promoting similar cancer-associated behaviors.
- Importantly, oncogene activation frequently interacts with alterations in tumor suppressor genes. Normal cells possess mechanisms that detect abnormal proliferation, DNA damage, or inappropriate signaling. Tumor suppressors such as p53 and RB can restrict cell-cycle progression or promote cellular responses that prevent damaged cells from expanding. If an oncogenic signal is activated while these protective mechanisms remain intact, the cell may undergo senescence, apoptosis, or another form of growth arrest. Additional alterations that disable these safeguards can therefore facilitate tumor development.
- The strength and duration of oncogenic signaling also matter. A temporary increase in growth signaling can be compatible with normal physiology, such as during tissue repair. Persistent activation is fundamentally different. When an oncogenic pathway remains active for extended periods, it can continuously stimulate proliferation, alter metabolism, suppress cell death, and reshape interactions with the cellular environment.
- Different oncogenes can also cooperate. For example, activation of one oncogenic pathway may stimulate proliferation while another alteration increases survival. A third alteration may enhance metabolic adaptation or promote genomic instability. Such oncogene cooperation helps explain why cancer is usually a multistep process rather than the consequence of a single molecular alteration.
- Cancer evolution can further modify oncogenic signaling over time. Once a cell acquires an activating alteration, descendants carrying that alteration may have a selective growth advantage. Additional mutations can subsequently arise, producing genetically and phenotypically diverse subclones. Treatment can impose another selective pressure, allowing resistant populations carrying alternative or secondary oncogenic alterations to expand.
- Modern cancer genomics has made it possible to identify many of these activating mechanisms across different tumor types. DNA sequencing can reveal point mutations and small insertions or deletions, copy-number analysis can identify amplification, and structural-variant analysis can detect chromosomal rearrangements. RNA sequencing can identify fusion transcripts and abnormal gene expression, while proteomic approaches can determine whether genomic alterations actually produce changes in protein abundance or signaling activity.
- The functional interpretation of an alteration remains important. Not every mutation in a cancer cell is an oncogenic driver. Some are passenger mutations that accumulate during tumor evolution without directly promoting cancer-cell fitness. Determining whether an alteration activates an oncogene therefore requires integration of genomic data with biochemical, cellular, and clinical evidence.
- These mechanisms also explain why different cancers can depend on different molecular drivers. One tumor may be dominated by an activating RAS mutation, another by receptor amplification, another by a fusion kinase, and another by transcriptional overexpression of an oncogenic regulator. Despite their differences, these alterations all disrupt the normal relationship between cellular signals and cellular behavior.
- Understanding how oncogenes are activated is essential for understanding why specific oncoproteins become attractive therapeutic targets. If a cancer depends on a mutant kinase, blocking its enzymatic activity may suppress tumor growth. If the driver is a receptor amplification, reducing receptor signaling may be effective. If the alteration produces a fusion protein, the unique structure or activity of the fusion may provide a selective therapeutic vulnerability.
- The major mechanisms of oncogene activation can therefore be summarized as four interconnected routes: mutation can alter protein activity; amplification can increase gene dosage; overexpression can increase protein abundance; and chromosomal rearrangement can deregulate gene expression or create fusion proteins. Additional layers involving transcription, epigenetics, RNA regulation, protein stability, and signaling-network interactions can further strengthen or modify these effects.
- Together, these mechanisms provide the molecular bridge between a normal proto-oncogene and an oncogenic state. The next articles can now examine individual examples in detail, beginning with RAS oncoproteins, which provide one of the clearest models of how a normal signaling protein can become a persistent driver of cancer.
